Table 2.
Attitude of the physicians of both groups regarding pharmacovigilance.
| Doctors attending CME | Doctors not attending CME | |
|---|---|---|
| Main purpose of ADR reporting system | ||
| Identify safe drugs | 25 | 42** |
| Measure the incidence of ADRs | 33 | 17* |
| Identify predisposing factors to ADRs | 26 | 8## |
| Identify new ADRs | 17 | 22 |
| Comparison of ADRs within the same class | 8 | 11 |
| Factors encouraging ADR reporting | ||
| Seriousness of ADR | 57 | 94# |
| Unusualness of ADR | 59 | 53 |
| New drug | 65 | 47** |
| Correct diagnosis | 12 | 21 |
| Well-recognised ADR | 24 | 36 |
| Factors discouraging ADR reporting | ||
| Reporting may be wrong | 42 | 38 |
| Lack of time | 45 | 38 |
| Single unreported case does not affect ADR database | 57 | 33# |
| Do not know where to report | 37 | 57** |
| Do not feel the need to report ADR | 19 | 21 |
| Negative impact on company marketing the drug | — | 3 |
| Is ADR reporting a professional obligation? | ||
| Yes | 51 | 61 |
| No | 13 | 28** |
| Do not know | 29 | 8* |
| Perhaps | 7 | 3 |
| Which ADR should be reported? | ||
| None | — | 1 |
| All | 36 | 56** |
| All serious ADRs | 55 | 39** |
| ADRs to new drugs | 32 | 11## |
| Unknown ADRs to old drugs | 7 | 7 |
| Opinion regarding establishment of ADR reporting centre | ||
| Should be in all hospitals | 68 | 58 |
| Not needed in all hospitals | 11 | 8 |
| One in a city | 10 | 10 |
| Depend on bed size | 16 | 21 |
| ADRs reporting should be | ||
| Compulsory | 48 | 64** |
| Voluntary | 38 | 15# |
| Rewarded | 2 | 9 |
| Hide the identity of prescriber | 6 | 6 |
| Hide the identity of reporter | 6 | 6 |
*P < 0.005; # P < 0.0001; **P < 0.05; ## P < 0.001.